Bexmarilimab
Hematological Cancers
Key Facts
About Faron Pharmaceuticals
Faron Pharmaceuticals is a Finland-based, publicly traded biotech focused on developing breakthrough immunotherapies that harness the patient's own immune system to fight cancer. The company's core achievement is the development of bexmarilimab, a first-in-class anti-Clever-1 antibody, which is in Phase I/II trials for hematological malignancies and has shown promise in solid tumors. Faron's strategy is to advance bexmarilimab through clinical development, initially in combination with standard-of-care, to address significant unmet needs in oncology and create a new pillar in the immuno-oncology landscape.
View full company profileAbout Faron Pharmaceuticals
Faron Pharmaceuticals is a Finland-based, publicly traded biotech focused on developing breakthrough immunotherapies that harness the patient's own immune system to fight cancer. The company's core achievement is the development of bexmarilimab, a first-in-class anti-Clever-1 antibody, which is in Phase I/II trials for hematological malignancies and has shown promise in solid tumors. Faron's strategy is to advance bexmarilimab through clinical development, initially in combination with standard-of-care, to address significant unmet needs in oncology and create a new pillar in the immuno-oncology landscape.
View full company profileTherapeutic Areas
Other Hematological Cancers Drugs
| Drug | Company | Phase |
|---|---|---|
| CAR-T/CD19 with TriTE construct | Beike Bio-Technology | Phase 1 |
| CTM-PNK | CytoMed Therapeutics | Preclinical |